Previous 10 | Next 10 |
Mind Medicine (NASDAQ:MNMD) said a mid-stage study showed beneficial effects of LSD and potential to safely mitigate symptoms of anxiety disorders. The company said that Matthias Liechti and Friederike Holze, MindMed collaborators at University Hospital Basel (UHB), reported data fr...
MindMed Collaborators Prof. Liechti and Dr. Holze Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety Disorders Canada NewsWire - Results from the placebo-controlled investigator-initiated trial, conducted at the University Hospital Basel (UHB),...
MindMed to Host Earnings Call to Discuss First Quarter 2022 Financial Results and Provide Business Update Canada NewsWire NEW YORK , May 9, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical st...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Tesla CEO Elon Musk recently stated on Twitter that psychedelic substances and other plant-based drugs were effective as treatments for a number of mental health conditions. Musk has in the past smoked a joint during a livestream video. The tweet in question is an excerpt from a conversa...
Every retail trader wants to find penny stocks with huge potential. Thanks to the rise of the “Ape” movement, the opportunity in the market was presented during the early days of the pandemic. Weathered stocks like GameStop ( NYSE: GME ) or Bed Bath & Beyond ( NASDAQ...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 28, 2022 – Oregon is set to become the first US state to market legal psilocybin , the psychoactive substance found in magic mushrooms. Authorities plan to greenlight a par...
Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) is set to present preliminary topline effectiveness and safety results from its phase IIa study, which involves the treatment of anxiety disorder using LSD in conjunction with therapy. Many, including investors, expect the trial...
Mind Medicine Inc is a psychedelic stock, aimed at developing non-recreational products that deliver medical treatment to mental health and addiction-related conditions. The psychedelic market is one that is projected to see explosive growth in the near future, however, it still faces...
MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results for LSD in Anxiety Disorders at PSYCH Symposium PR Newswire - "LSD as a Treatment for Anxiety Disorders: New Evidence of Efficacy" will present the most recent and robust data on LSD in...
News, Short Squeeze, Breakout and More Instantly...
Mind Medicine (MindMed) Inc. Company Name:
MNMD Stock Symbol:
NASDAQ Market:
Mind Medicine (MindMed) Inc. Website:
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Stephanie Fagan, effective today, as Chief Corpo...
2024-07-26 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- New patent covers MM120 ODT formulation and extends patent term to 2041- - Claims include pharmaceutical formulation, methods of manufacturing and methods of treatment for MM120 ODT- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed...